RYR2 is frequently mutated in breast cancer, and its mutations can enhance the infiltration of cytotoxic T lymphocytes, activate memory CD4+ T cells and M1 macrophages to enhance antitumor immune responses (Xu et al., 2021). Here, RYR2 is linked to breast carcinoma.